Global Personalized Cancer Vaccines Market - 2020-2027

Global Personalized Cancer Vaccines Market - 2020-2027

Market Overview

The Global Personalized Cancer Vaccines Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

A cancer vaccine is a vaccine considered biological response modifiers that either treat existing cancer or prevent cancer development. Vaccines that treat existing cancer are known as therapeutic cancer vaccines. Preventive cancer vaccines are used in healthy people to prevent cancer. Some of the vaccines are ""autologous,"" being prepared from samples taken from the patient, and are specific to that patient. Personalized cancer vaccines are a highly emerging treatment option that uses a patient's cancer cells to develop a vaccine intended to teach their immune system how to recognize and destroy their cancer. These cancer cells have DNA mutations that differ from the DNA in normal, healthy cells different from patient to patient, which is where the concept of a personalized vaccine is developed. For instance, Combining the personalized vaccine with Pembrolizumab, an immunotherapy medicine that works with the immune system to fight certain types of cancers, will hopefully allow further benefit to patients than pembrolizumab alone.

Market Dynamics

The global Personalized Cancer Vaccines market growth is driven by the growing incidence of Cancer cases, Increasing demand for therapies, Strong pipeline of drugs and advanced technological facilities are among the key factors driving market growth.

Growing incidence of cancer cases globally, is expected to drive the global Personalized Cancer Vaccines market growth.

As per the World Health Organization (WHO), Cancer is the second-most leading cause of death worldwide, accounting for over 18.1 million cases were diagnosed in 2018. In 2020, around 19 Mn new cancer cases were diagnosed across the world as per the WHO. Likewise, the American Cancer Society reported that 89,500 cases were diagnosed in the U.S. in 2020. Additionally, according to International Agency for Research on Cancer (IARC) estimates, by 2040, global cancer cases are expected to grow to 27.5 million new cancer cases worldwide. This number has led to an increase in the adoption of various personalized cancer vaccines.

Robust clinical pipeline of novel vaccines, is expected to drive the global Personalized Cancer Vaccines market growth.

The prevalence of cancer worldwide is driving many vendors in the market to develop novel vaccines. As per the clinical trials.gov,

High Cost Associated Treatment is likely to hinder the global Personalized Cancer Vaccines market growth

As per the data published in the BMC health services article on 03 June 2020, estimating the costs of genomic sequencing in cancer control, the per-person costs were US$240–29 for targeted panels, US$604–1932 for exome sequencing, and US$2006-3347 for whole-genome sequencing. These factors are hindering the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted healthcare systems globally and majorly on the Personalized Cancer Vaccines. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types - breast, colorectal, lung, pancreatic, gastric, and esophageal cancers. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually.

Segment Analysis

Based on the Cancer Type, the global Personalized Cancer Vaccines market is segmented into Cervical cancer, Prostate cancer, Glioblastoma, Others

Cervical cancer segment accounts largest share due to high incidence of people infected with HPV virus associated cancers. Human Papilloma Virus (HPV) is a recognized major cause of cancer. Although most HPV infections are asymptomatic and clear spontaneously, persistent infections can progress to precancer or cancer. HPV causes most cervical cancers, as well as some cancers of the vagina. Cervical cancer is the most common HPV-associated cancer among women. Based on data in Centers for Disease Control and Prevention (CDC) from 2013 to 2017, about 45,300 new cases of HPV-associated cancers occurred in the United States each year, including about 25,400 among women. As per the American Cancer Society, it estimates about 14,480 new cases by 2021. For instance, the study is to evaluate a bivalent HPV vaccine, Cecolin®, in alternate 2-dose regimens, compared to an established HPV vaccine, Gardasil® (2006 FDA approved drug for cervical cancer) used as the comparator vaccine is currently under Phase 3 trials conducted by PATH global health organization in Collaboration with Leidos Biomedical Research, Inc., USA, Emmes Company, LLC, Biotech Co., Ltd.

Prostate cancer

According to WHO, Prostate cancer cases estimated in 2020 were 1.41 million. For instance, the study is to evaluate the safety and effectiveness of PROSTVAC (is a therapeutic cancer vaccine for prostate cancer) in Combination with Nivolumab (anti-PD-1) in Men with Prostate Cancer is currently undergoing Phase1/2 trials conducting by National Cancer Institute (NCI).

Glioblastoma

A glioblastoma is an aggressive form of cancer that can occur in the brain or spinal cord. As per the American Cancer Society’s estimates, by 2021 brain and spinal cord tumors in the United States, including adults and children, about 24,530 malignant tumors of the brain or spinal cord (13,840 in males and 10,690 in females) diagnosed. For instance, Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived cancer Vaccine in Patients with Newly Diagnosed Glioblastoma conducting by Adilia Hormigo in Collaboration with NovoCure Ltd.

Based on Vaccine Type, the global Personalized Cancer Vaccines market is segmented into Peptide-based, Dendritic Cell, DNA & RNA Cancer Vaccines, others.

To create a Personalized cancer vaccine, researchers identified cancer-specific peptides called neoantigens, then use a cell-, protein-, or nucleic acid-based platform to deliver those neoantigens to patients to prime the immune system to attack the tumor. Antigen-presenting cells such as Dendritic cells internalize the cancer-specific peptides selected for a personalized cancer vaccine and display them on their surface with the help of major histocompatibility complex (MHC) proteins. This, in turn, triggers T cells with receptors that bind those neoantigens to differentiate into effector, or killer, T cells that mobilize an immune reaction against cancer cells.

Dendritic Cell Vaccines

Monocytes are extracted from the bloodstream of patients and cultured with synthetic forms of selected cancer neoantigens to form mature dendritic cells carrying those neoantigens. These cells are then reinfused into the patient's blood circulation. For instance, the purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate own immune system to react to melanoma cells foll0wed by treatment with pembrolizumab (anti-PD-1 therapy) is currently under phase 1 trial by the University of Pennsylvania.

Peptide-based Vaccines

Synthetic peptides containing the neoantigen sequences are injected into the body, where they are picked up by antigen-presenting cells, for instance, currently under Phase 1 study of a Personalized Tumour Vaccine Strategy (Poly ICLC) and PD-1 Blockade (Nivolumab) in Patients with Follicular Lymphoma conducting by Washington University School of Medicine, Bristol-Myers Squibb.

DNA & RNA Cancer Vaccines

Nucleic acids encoding the neoantigens are introduced into the body, where they are translated into proteins and picked up by antigen-presenting cells. For instance, A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of autogene cevumeran (RO7198457) as a Single Agent and in Combination with Atezolizumab (anti-PD-1) in Patients with Locally Advanced or Metastatic Tumours is conducting by Genentech, Inc in Collaboration with BioNTech SE.

Based on End-User, the global Personalized Cancer Vaccines market is segmented into Hospitals, Cancer Research centers, clinics, others.

Due to the growing patient population, the hospitals segment held the largest market share. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment. Also the medications can only be administrated by intravenously under supervision of medical practioners at these locations.

Geographical Analysis

North America holds the largest market in the global cancer stem cells market due to the high incidence of cancer, according to the International Agency for Research on Cancer (IARC), which claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and immunotherapy methods, the total availability of advanced technological tools, FDA approval of new drugs and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Phase I Trial of Tumor Neoantigen Vaccine to treat cancer by Henan Cancer Hospital.

Competitive Landscape

The Global Personalized Cancer Vaccines Market is quite competitive with some key competitors like Genocea Biosciences, Inc., Advaxis Inc, BioNtech S E, Celldex Therapeutics, Bristol-Myers Squibb, Genentech, Gritstone Oncology, Merck & Co, Moderna Therapeutics, Neon Therapeutics. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market’s growth globally. For instance, Gritstone Oncology, Inc, in collaboration with Bristol-Myers Squibb Phase 1/2 Study of GRT-C901/GRT-R902, a personalized neoantigen cancer vaccine with nivolumab and ipilimumab (Immune Checkpoint Blockade) for Patients with Advanced Solid Tumors.

BioNTech SE

Overview: BioNTech SE (Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to treating diseases. BioNTech was founded in 2008 based on research by Ugur Sahin, Ozlem Tureci and Christoph Huber, with a seed investment of €150 million. The company's activities focus on the development and production of technologies and drugs for individualized cancer immunotherapy. Andreas and Thomas Strungmann, Michael Motschmann, and Helmut Jeggle were cofounders. In 2009, the acquisition of EUFETS and JPT Peptide Technologies took place. In 2013, Katalin Kariko joined BioNTech as a senior vice president.

In 2020, BioNTech, in conjunction with Pfizer, developed the RNA vaccine BNT162b2 for preventing COVID-19 infections, which offers a 95% efficacy.

Product Portfolio: The Company’s portfolio comprised of include it develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, vaccines against infectious diseases and as protein replacement therapies for rare diseases, and engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.

Product- BNT141 in multiple solid tumors.

Key developments:

BioNTech together with Sanofi SAR441000 (BNT131) is being studied in a Phase 1 basket clinical trial as a monotherapy in patients with advanced melanoma and in combination with an anti-PD-1/PD-L1 checkpoint inhibitor in patients with advanced melanoma and certain solid tumors.

Why Purchase the Report?
• Visualize the composition of the global Personalized Cancer Vaccines market segmentation by Target Type, by Application, by End-User and region highlighting the key commercial assets and players.
• Identify commercial opportunities in Personalized Cancer Vaccines market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of Personalized Cancer Vaccines market- level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players

The global Personalized Cancer Vaccines report would provide an access to an approx. market data 61 tables, 55 figures and 240 pages.

Target Audience
• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers